Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
Avant Technologies Inc. logo

OTC · AVAI

Avant Technologies Inc.

Technology · Software - Application

$0.10

Up+$0.01 (+5.26%)

Updated Nov 5, 2026, 10:39 AM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
43.49M
P/E ratio
-39.42
Dividend yield
0.00%
52-week range
$0.25 – $0.83
Volume
294.37K
Avg. volume
97.6K

Price performance · AVAI

AVAI price history

1M range · 0 trading sessions · Daily adjusted prices

AVAI does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest AVAI news

The latest Smart Investors Daily articles mentioning AVAI.

Stock researchCompany · Overview

AVAI research

Overview

Company profile and research snapshot.

Company profile

AVANT TECHNOLOGIES INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

Avaí Bio and Austrianova Announce Publication in Frontiers in Aging Journal Highlighting Novel Cell Encapsulation-Based Approach to Sustained Klotho Delivery

LAS VEGAS, NV, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotech developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, together with its joint venture partner Austrianova, today announced the publication of a peer-reviewed article in Frontiers in Aging, entitled, “Maintaining Klotho: Preventing the Body from Unwinding.” The article, authored by Austrianova researchers, appears in the journal

Yahoo · Oct 7, 2026

Avaí Bio and Austrianova Hold First Joint Steering Committee Meeting with Ospedale San Raffaele for Diabetes Cell Therapy Program

LAS VEGAS, NEVADA, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and its joint venture partner Austrianova, today announced the first joint steering committee meeting for their collaboration with Ospedale San Raffaele S.r.l. (OSR), to discuss the initial research program for evaluating an encapsulated beta-cell replacement approach for insulin-dependent diabetes. The meeting brought together Prof. Lorenzo Piemonti, Director of the Diabetes Research Inst

Yahoo · Sep 30, 2026

Avaí Bio and Austrianova Successfully Encapsulate GMP-Quality Klotho-Producing Cells, Achieve Robust Klotho Secretion

LAS VEGAS, NEVADA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotech developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, together with its joint venture partner Austrianova, today announced the successful encapsulation of GMP-quality Klotho-producing cells in the joint venture’s signature technology, Cell-in-a-Box® capsules. After the successful completion of comprehensive adventitious ag

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By